The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
In Vivo Pharmacokinetics and Regulation of Gene Expression Profiles by Isothiocyanate Sulforaphane in the Rat
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 3×
“, 2003) followed by the release of Nrf2 from its cytosolic partner Keap1 (Itoh et al., 1999) with the subsequent nuclear translocation and binding to its partners (small Mafs) to exert its transcriptional activity on the ARE of these genes (Venugopal and Jaiswal, 1996; Itoh et al.”
BackgroundNguyen, T., Sherratt, P. J., Huang, H.-C., Yang, C. S., & Pickett, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207293200 · Cited by 615
Cited by
Induction of phase I, II and III drug metabolism/transport by xenobiotics
Xu, C., Li, C. Y.-T., & Kong, A.-N. T. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977789 · Cited by 1,279
Self-citationMolecular mechanisms of Nrf2‐mediated antioxidant response
Li, W., & Kong, A. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20465 · Cited by 785
Self-citationMulti-targeted prevention of cancer by sulforaphane
Clarke, J. D., Dashwood, R. H., & Ho, E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.018 · Cited by 563
Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway
Hayes, J. D., McMahon, M., Chowdhry, S., & Dinkova-Kostova, A. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3221 · Cited by 539
A Novel Mechanism of Chemoprotection by Sulforaphane
Myzak, M. C., Karplus, P. A., Chung, F.-L., & Dashwood, R. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1326 · Cited by 494
The cancer chemopreventive actions of phytochemicals derived from glucosinolates
Hayes, J. D., Kelleher, M. O., & Eggleston, I. M. (2008) · European Journal of Nutrition · doi:10.1007/s00394-008-2009-8 · Cited by 404
Singh, S. V., Srivastava, S. K., Choi, S., Lew, K. L., Antosiewicz, J., Xiao, D., Zeng, Y., Watkins, S. C., Johnson, C. S., Trump, D. L., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412443200 · Cited by 366
Molecular Targets of Dietary Phenethyl Isothiocyanate and Sulforaphane for Cancer Chemoprevention
Cheung, K. L., & Kong, A.-N. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9162-8 · Cited by 364
Self-citationSulforaphane induces cell type–specific apoptosis in human breast cancer cell lines
Pledgie-Tracy, A., Sobolewski, M. D., & Davidson, N. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0494 · Cited by 335
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Self-citationAxelsson, A. S., Tubbs, E., Mecham, B., Chacko, S., Nenonen, H. A., Tang, Y., Fahey, J. W., Derry, J. M. J., Wollheim, C. B., Wierup, N., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4477 · Cited by 323
Protective effect of sulforaphane against oxidative stress: Recent advances
Guerrero-Beltrán, C. E., Calderón-Oliver, M., Pedraza-Chaverri, J., & Chirino, Y. I. (2012) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2010.11.005 · Cited by 320
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast
Cornblatt, B. S., Ye, L., Dinkova-Kostova, A. T., Erb, M., Fahey, J. W., Singh, N. K., Chen, M.-S. A., Stierer, T., Garrett-Mayer, E., Argani, P., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm049 · Cited by 320
Myzak, M. C., Hardin, K., Wang, R., Dashwood, R. H., & Ho, E. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi265 · Cited by 306
Xu, C., Shen, G., Chen, C., Gélinas, C., & Kong, A.-N. T. (2005) · Oncogene · doi:10.1038/sj.onc.1208656 · Cited by 301
Self-citationEnhancing Expression of Nrf2-Driven Genes Protects the Blood–Brain Barrier after Brain Injury
Zhao, J., Moore, A. N., Redell, J. B., & Dash, P. K. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1683-07.2007 · Cited by 274
KEAP1 and done? Targeting the NRF2 pathway with sulforaphane
Dinkova-Kostova, A. T., Fahey, J. W., Kostov, R. V., & Kensler, T. W. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.02.002 · Cited by 273
Xu, C., Yuan, X., Pan, Z., Shen, G., Kim, J.-H., Yu, S., Khor, T. O., Li, W., Ma, J., & Kong, A.-N. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0497 · Cited by 261
Self-citationEmerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders
Uddin, M. S., Mamun, A. A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M. A., Mathew, B., Abdel-Daim, M. M., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135624 · Cited by 154
Cytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen Species
Sestili, P., & Fimognari, C. (2015) · BioMed Research International · doi:10.1155/2015/402386 · Cited by 90
Metadata
- Authors
- Hu, R., Hebbar, V., Kim, B.-R., Chen, C., Winnik, B., Buckley, B., Soteropoulos, P., Tolias, P., Hart, R. P., & Kong, A.-N. T.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 310
- Issue
- 1
- Pages
- 263-271
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2116978833
- Cited by
- 219
- References
- 3
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.